Aktis Oncology (NASDAQ:AKTS) Price Target Raised to $33.00

Aktis Oncology (NASDAQ:AKTS) had its price objective upped by HC Wainwright from $30.00 to $33.00 in a research note released on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the technology company’s stock. HC Wainwright also issued estimates for Aktis Oncology’s Q1 2026 earnings at ($0.36) EPS, Q2 2026 earnings at ($0.38) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.51) EPS, FY2026 earnings at ($1.72) EPS, Q1 2027 earnings at ($0.54) EPS, Q2 2027 earnings at ($0.57) EPS, Q3 2027 earnings at ($0.60) EPS, Q4 2027 earnings at ($0.63) EPS and FY2027 earnings at ($2.35) EPS.

AKTS has been the subject of several other research reports. Wall Street Zen raised Aktis Oncology to a “hold” rating in a research note on Saturday, January 17th. TD Cowen assumed coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They issued a “buy” rating for the company. Leerink Partners started coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They set an “outperform” rating and a $31.00 price target on the stock. JPMorgan Chase & Co. assumed coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They set an “overweight” rating and a $30.00 price target on the stock. Finally, Bank of America initiated coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Aktis Oncology presently has a consensus rating of “Buy” and an average target price of $32.00.

Aktis Oncology Trading Up 1.8%

Shares of AKTS stock opened at $17.37 on Tuesday. Aktis Oncology has a fifty-two week low of $14.72 and a fifty-two week high of $29.16. The business has a 50-day moving average price of $19.03.

Insider Transactions at Aktis Oncology

In other Aktis Oncology news, Director Helen Susan Kim purchased 835,000 shares of the company’s stock in a transaction on Monday, January 12th. The shares were bought at an average cost of $18.00 per share, with a total value of $15,030,000.00. Following the transaction, the director directly owned 5,671,825 shares in the company, valued at approximately $102,092,850. This represents a 17.26% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Ecor1 Capital, Llc purchased 2,222,222 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were acquired at an average price of $18.00 per share, with a total value of $39,999,996.00. Following the completion of the acquisition, the director owned 4,348,658 shares of the company’s stock, valued at approximately $78,275,844. The trade was a 104.50% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have acquired 6,117,776 shares of company stock worth $110,119,968. Insiders own 3.30% of the company’s stock.

Aktis Oncology News Roundup

Here are the key news stories impacting Aktis Oncology this week:

• Positive Sentiment: HC Wainwright raised earnings estimates across 2026 and 2027 quarters and kept a “Buy” rating with a $33 price target — the analyst materially reduced expected losses for Q1–Q4 2026 (e.g., Q1: from ($0.64) to ($0.36); Q2: ($0.71) to ($0.38); Q3: ($0.77) to ($0.46); Q4: ($0.83) to ($0.51)) and lifted FY2026 and FY2027 loss estimates (FY2026: ($2.95) to ($1.72); FY2027: ($3.71) to ($2.35)). That optimism is likely driving buying interest. Aktis Oncology (NASDAQ:AKTS) Stock Price Expected to Rise, HC Wainwright Analyst Says
• Positive Sentiment: Aktis announced FDA clearance of investigational new drug (IND) applications for AKY-2519 and provided business updates and full?year 2025 financial results — IND clearances are a clear clinical development catalyst that can increase the stock’s upside if trials progress on schedule. Aktis Oncology Announces FDA Clearance of INDs for AKY-2519
• Neutral Sentiment: Market data and coverage references (e.g., Barron’s stock page) provide third?party visibility but add no immediate catalyst; useful for background research. Aktis Oncology Inc. — Barron’s
• Negative Sentiment: Despite upgrades and IND clearance, consensus fundamentals remain loss-making (current full?year consensus ? ($0.43) EPS) and the stock trades below its 50?day moving average—ongoing development risk, cash burn and execution risk could pressure the share price if clinical or financing developments disappoint.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.